Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): long-term follow-up from the onasemnogene abeparvovec phase 1/2a clinical trial

被引：0
|
作者：
Mendell, J. [1 ]
Shell, R. [1 ]
Lehman, K. [1 ]
McColly, M. [1 ]
Lowes, L. [1 ]
Alfano, L. [1 ]
Miller, N. [1 ]
Iammarino, M. [1 ]
Church, K. [1 ]
Ogrinc, F. [2 ]
Ouyang, H. [2 ]
Kernbauer, E. [2 ]
Shah, S. [2 ]
L'Italien, J. [2 ]
Sproule, D. [2 ]
Feltner, D. [2 ]
Al-Zaidy, S. [1 ]
机构：
[1] Nationwide Childrens Hosp, Columbus, OH USA
[2] AveXis Inc, Bannockburn, IL USA
来源：
NEUROMUSCULAR DISORDERS | 2019年 / 29卷
关键词：
D O I：
10.1016/j.nmd.2019.06.513
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.351
引用
收藏
页码：S184 / S184
页数：1
相关论文
共 50 条
  • [1] Gene-replacement therapy (GRT) in spinal muscular atrophy type 1 (SMA1): Long-term follow-up from the onasemnogene abeparvovec phase 1/2A clinical trial
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Spector, S. A.
    Ogrinc, F. G.
    Ouyang, H.
    Kernbauer, E.
    Shah, S.
    L'Italien, J.
    Sproule, D. M.
    Feltner, D. E.
    Al-Zaidy, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [2] Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Onasemnogene Abeparvovec Phase 1/2a Clinical Trial
    Mendell, J.
    Shell, R.
    Lehman, K.
    McColly, M.
    Lowes, L.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Church, K.
    Ogrinc, F.
    Ouyang, H.
    Kernbauer, E.
    Shah, S.
    L'Italien, J.
    Sproule, D.
    Feltner, D.
    Al-Zaidy, S.
    ANNALS OF NEUROLOGY, 2019, 86 : S126 - S126
  • [3] Long-term follow-up of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1 (SMA1)
    Mendell, J.
    Shell, R.
    Lehman, K.
    McColly, M.
    Lowes, L.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Church, K.
    Ogrinc, F.
    Ouyang, H.
    Kernbauer, E.
    Joshi, S.
    Sproule, D.
    Meriggioli, M.
    Feltner, D.
    Al-Zaidy, S.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S122 - S123
  • [4] Gene Therapy in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up (LTFU) From the Onasemnogene Abeparvovec Phase 1 Clinical Trial
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Baldinetti, F.
    Ogrinc, F. G.
    Ouyang, H.
    Kernbauer, E.
    Joshi, S.
    Sproule, D. M.
    Meriggioli, M.
    Feltner, D. E.
    Al-Zaidy, S.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 165 - 165
  • [5] Gene-Replacement Therapy in Spinal Muscular Atrophy Type 1: Long-Term Follow-Up From the Onasemnogene Abeparvovec-xioi Phase 1/2a Clinical Trial
    Mendell, Jerry R.
    Shell, Richard
    Lehman, Kelly J.
    McColly, Markus
    Lowes, Linda P.
    Alfano, Lindsay N.
    Miller, Natalie F.
    Iammarino, Megan A.
    Church, Kathleen
    Ogrinc, Francis G.
    Ouyang, Haojun
    Kernbauer, Elaine
    Joshi, Shivani
    Sproule, Douglas M.
    Meriggioli, Matthew
    Feltner, Douglas E.
    Al-Zaidy, Samiah
    NEUROLOGY, 2020, 94 (15)
  • [6] AVXS-101 Gene-Replacement Therapy (GRT) in Spinal Muscular Atrophy Type 1 (SMA1): Long-Term Follow-Up From the Phase 1 Clinical Trial
    Mendell, Jerry R.
    Lehman, Kelly J.
    McColly, Markus
    Lowes, Linda P.
    Alfano, Lindsay N.
    Miller, Natalie F.
    Iammarino, Megan A.
    Church, Kathleen
    Ogrinc, Francis G.
    L'Italien, James
    Wells, Courtney
    Sproule, Douglas M.
    Feltner, Douglas E.
    NEUROLOGY, 2019, 92 (15)
  • [7] Onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy Type 1 (SMA1): Pivotal phase 3 study (STR1VE) update
    Day, J.
    Chiriboga, C.
    Crawford, T.
    Darras, B.
    Finkel, R.
    Connolly, A.
    Iannaccone, S.
    Kuntz, N.
    Pena, L.
    Schultz, M.
    Shieh, P.
    Smith, E.
    Feltner, D.
    Ogrinc, F.
    Ouyang, H.
    Macek, T.
    Kernbauer, E.
    Sproule, D.
    Mendell, J.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S183 - S183
  • [8] Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) for Spinal Muscular Atrophy Type 1 (SMA1): Pivotal Phase 3 Study (STR1VE) Update
    Day, J.
    Chiriboga, C.
    Crawford, T.
    Darras, B.
    Finkel, R.
    Connolly, A.
    Iannaccone, S.
    Kuntz, N.
    Pena, L.
    Schultz, M.
    Shieh, P.
    Smith, E.
    Feltner, D.
    Ogrinc, F.
    Shah, A.
    Ouyang, H.
    Macek, T.
    Kernbauer, E.
    L'Italien, J.
    Sproule, D.
    Kaspar, B.
    Mendell, J.
    ANNALS OF NEUROLOGY, 2019, 86 : S118 - S121
  • [9] Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy (SMA) type 1
    Mendell, J.
    Wigderson, M.
    Alecu, I.
    Yang, L.
    Mehl, L.
    Connolly, A.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S91 - S91
  • [10] LONG-TERM FOLLOW-UP OF THE PHASE 1 START TRIAL OF ONASEMNOGENE ABEPARVOVEC GENE THERAPY IN SPINAL MUSCULAR ATROPHY TYPE 1
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Kausar, I.
    Reyna, S. P.
    Meriggioli, M.
    Kleyn, A.
    Al-Zaidy, S.
    THORAX, 2021, 76 : A10 - A10
12345